Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eddingpharm, GSK in Commercialization Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Eddingpharm, GSK in Commercialization Pact

Acquires rights to Tykerb in China

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eddingpharm, a specialty pharma company in China, has entered into a collaboration agreement with GlaxoSmithKline China, to acquire exclusive rights in China to commercialize and distribute Tykerb, GSK’s treatment for advanced or metastatic breast cancer.
 
Tykerb, recently approved by the China State Food and Drug Administration (SFDA), is used in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy with an anthracycline, a taxane and trastuzumab.
 
Mr. Xin Ni, chairman and chief executive officer of Eddingpharm, said, “This cooperation with GSK on Tykerb is not only a milestone of Eddingpharm’s business development history, but also an important milestone of China’s pharmaceutical industry. This is the first time a Chinese pharmaceutical company will participate in the launch of a proprietary global oncology drug.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters